Antiangiogenic drugs as a novel anticancer therapeutic strategy: Which are the more promising agents? What are the clinical developments and indications?
- 31 December 1997
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 26 (3) , 147-162
- https://doi.org/10.1016/s1040-8428(97)10001-4
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Cancer UndefeatedNew England Journal of Medicine, 1997
- Combined modality therapy of solid tumoursThe Lancet, 1997
- Antiangiogenesis for cancer therapyThe Lancet, 1997
- ChemotherapyThe Lancet, 1997
- Reciprocal paracrine interactions between tumour cells and endothelial cells: the ‘angiogenesis progression’ hypothesisEuropean Journal Of Cancer, 1996
- Modulation of the Organ Microenvironment for Treatment of Cancer MetastasisJNCI Journal of the National Cancer Institute, 1995
- Does improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells?European Journal Of Cancer, 1994
- Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agentsBioEssays, 1991
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971